Terminated PHASE2 NCT00216138

Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck

A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40

Sponsor: Hoffmann-La Roche

Conditions Head and Neck Cancer

Interventions Capecitabine Docetaxel Premedication

Updated 6 times since 2017 Last updated: Apr 28, 2011 Started: Mar 31, 2004 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This PHASE2 trial investigates Head and Neck Cancer and is currently terminated or withdrawn. Hoffmann-La Roche leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche
Hoosier Cancer Research Network
Sanofi
Walther Cancer Institute

Data source: Hoosier Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Chicago, United States , Elkhart, United States , Evansville, United States , Fort Wayne, United States , Goshen, United States , Indianapolis, United States , Jackson, United States , Lafayette, United States , Muncie, United States and 6 more locations